A Study of BufferGel in Women
Phase I Vaginal Microbicide Study of BufferGel
The purpose of this study is to see if it is safe to use BufferGel in the vaginas of women who do not have HIV and who have a low risk of getting HIV.
Many new cases of HIV are the result of heterosexual activity. Condom use is currently the only effective way of preventing the spread of HIV and other sexually transmitted diseases (STDs). However, women, who have a greater risk of getting HIV, are often unable to convince their partner to use a condom. Therefore, it is important to develop methods that prevent the spread of HIV and that are controlled by the woman, such as medicines used in the vagina. BufferGel is known to kill the organisms that cause STDs, including HIV. BufferGel may do this without causing genital irritation and sores as other medicines do. More studies are needed to see if this is true.
調査の概要
詳細な説明
Heterosexual transmission of HIV presently accounts for the vast majority of new HIV infections worldwide. Currently the condom is the only method available that has been shown to be effective against HIV and other sexually transmitted diseases (STDs). However, women who are at the greatest risk for acquiring HIV are often unable to negotiate condom use. Therefore, it is important that effective female-controlled barrier methods, such as topical microbicides, be made available to women. BufferGel has sufficient buffer capacity to acidify twice its own volume in human semen, which inactivates STD pathogens, including HIV. Unlike most other topical microbicides, BufferGel is non-detergent so it should not cause genital irritation and lesions. The safety and acceptability of BufferGel still need to be studied more carefully.
Participants are divided into two cohorts. Cohort IA consists of sexually abstinent women and cohort IB consists of sexually active women. Within each U.S. cohort, participants are assigned to apply BufferGel either once or twice daily. Within each international cohort, all participants apply BufferGel twice daily. Participants apply BufferGel for 14 days. Pelvic examinations are performed at Days 7 and 14.
研究の種類
入学
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Rhode Island
-
Pawtucket、Rhode Island、アメリカ、02860
- Mem Hosp of Rhode Island
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
All participants must have:
- HIV-negativity by licensed EIA.
- Willingness and ability to complete a study diary.
- A regular menstrual cycle with a minimum of 18 days between menses.
- Ability to insert BufferGel daily as required by the protocol.
Cohort IA participants must:
- Agree to abstain from sexual intercourse for the duration of the study.
Cohort IB participants must:
- Agree to have vaginal intercourse at least 2 times per week and use non-lubricated condoms for each act of intercourse.
- Have currently (for 3 months or longer) a single sexual partner who is at low-risk for HIV infection.
Exclusion Criteria
Co-existing Condition:
Participants with the following conditions or symptoms are excluded:
- A Grade 3 or higher liver, renal, or hematology abnormality.
- Menopausal.
- Breakthrough menstrual bleeding.
- Any STD or symptoms, as seen on pelvic exam, consistent with an STD or other genital tract infection or trauma including vaginitis, cervicitis, edema, erythema, ecchymosis, petechial hemorrhage, vulvar or cervicovaginal lesions or abrasions, subepithelial hemorrhage, or signs of genital tract infection (other than asymptomatic bacterial vaginosis) from laboratory evaluations.
Concurrent Medication:
Excluded:
- Any vaginal product other than BufferGel, including lubricants and feminine hygiene products.
- Vaginal drying agents.
- Douche.
- Participation in any other microbicide or contraceptive study.
- Treatment for any STD.
Participants with the following prior conditions are excluded:
- IUD, abnormal PAP smear, pregnancy, abortion, or gynecologic surgery in the last 3 months.
- Any of the following side effects related to Depo-provera use in the past 2 months:
- headaches, dizziness, abdominal pain, fatigue, or nervousness.
Prior Medication:
Excluded:
- A course of antibiotic therapy (other than treatment for malaria) in the last 14 days.
- Any spermicide within the past month.
- Initiation of Depo-provera for contraceptive purposes in the last 6 months.
Risk Behavior:
Excluded:
- Use of intravenous drugs currently or within the past year.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
協力者と研究者
捜査官
- スタディチェア：Kenneth Mayer
- スタディチェア：Kenrad Nelson
出版物と役立つリンク
一般刊行物
- van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):21-7. doi: 10.1097/00126334-200101010-00003.
- Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis. 2001 Feb 1;32(3):476-82. doi: 10.1086/318496. Epub 2001 Jan 26.
研究記録日
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。